Related Experiment Video

Updated: Jun 21, 2026

Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes
03:53

Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes

Published on: April 19, 2024

[Cefditoren and community-acquired lower respiratory tract infections (corrected)]

J Barberán1, J Mensa

  • 1Servicio de Enfermedades Infecciosas, Hospital Central de la Defensa "Gómez Ulla" Madrid. josebarberan@teleline.es

Revista Espanola De Quimioterapia : Publicacion Oficial De La Sociedad Espanola De Quimioterapia
|August 8, 2009
PubMed

Insights

Cefditoren, an oral cephalosporin, effectively treats respiratory infections caused by common pathogens like Streptococcus pneumoniae and Haemophilus influenzae. It demonstrates high bacteriologic response rates, making it a reliable option for acute exacerbations of chronic bronchitis and community-acquired pneumonia.

Area of Science:

  • Pharmacology
  • Microbiology
  • Infectious Diseases

Background:

  • Cefditoren is a third-generation oral cephalosporin antibiotic.
  • It exhibits activity against key respiratory tract pathogens, including resistant strains.

Purpose of the Study:

  • To evaluate the efficacy of cefditoren against respiratory pathogens.
  • To assess its suitability for treating lower respiratory tract infections.

Main Methods:

  • Minimum inhibitory concentration (MIC) was used to measure bacterial activity.
  • Target attainment (T > MIC) was considered for clinical outcomes.
  • Bacteriologic response rates were analyzed for key pathogens.

Main Results:

  • Cefditoren shows potent activity against S. pneumoniae and H. influenzae, including resistant strains.
  • High bacteriologic response rates were observed (approx. 85% for H. influenzae, 90% for S. pneumoniae).
  • It is effective for switch therapy from intravenous cephalosporins.

Conclusions:

  • Cefditoren is a reliable oral option for treating acute exacerbations of chronic bronchitis and community-acquired pneumonia.
  • Its pharmacokinetic profile supports its use in respiratory tract infections.

More Related Videos

Cystic Fibrosis Aggregate Biofilm Model to Study Infection-relevant Gene Expression08:58

Cystic Fibrosis Aggregate Biofilm Model to Study Infection-relevant Gene Expression

Published on: April 18, 2025

Related Concept Videos

Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Microbiota of the Respiratory Tract01:29

Microbiota of the Respiratory Tract

The human respiratory tract, comprising the upper and lower segments, serves as a critical interface with the external environment. The upper respiratory tract (URT)—including the nostrils, sinuses, pharynx, and oropharynx—is heavily colonized by microbes, while the lower respiratory tract (LRT), composed of the larynx, trachea, bronchi, and lungs, was long thought to be sterile. However, recent molecular studies have revealed that the lungs are not devoid of microbes but act more like...
Respiratory Syncytial Virus Disease01:29

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...
Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...